Adgar0.1%

Adgar 0.1% cream or gel is indicated for topical treatment of acne vulgaris.

Topical retinoid and related preparations

Adgar 0.1% acts on retinoid receptors that are commonly found in the skin of face, back and chest. Biochemical and pharmacological studies have demonstrated that Adgar 0.1% is a modulator of cellular differentiation, keratinization, and inflammatory processes, all of that represent important features in the pathology of acne vulgaris. Adgar 0.1% binds with specific retinoic acid nuclear receptors that normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. Absorption of Adgar 0.1% through human skin is low.

Adgar 0.1% 0.1% cream: It should be applied to the affected areas of skin, once daily at night-time.Adgar 0.1% 0.3% gel: It should be applied to the entire face and any other affected areas of the skin, once daily in the evening.A thin film of gel or cream should be applied to the skin areas where lesions present, using enough to cover the entire affected areas lightly

Adgar 0.1% 0.1%: It should be applied to the affected areas of skin, once daily at night-time.Adgar 0.1% 0.3%: It should be applied to the entire face and any other affected areas of the skin, once daily in the evening.Children below 12 years of age: Safety and effectiveness in children below 12 years of age have not been established.

A thin film of gel or cream should be applied to the skin areas where lesions present, using enough to cover the entire affected areas lightly.

Concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution. Exercise particular caution in using preparations containing sulfur, resorcinol or salicylic acid in combination with Adgar 0.1%. If any of these preparations have been used, it is advisable not to start therapy with Adgar 0.1% until the effects of such preparations in skin have subsided. If combined use of both medications is important, it is better to use in two different times.

Adgar 0.1% should not be administered to individuals who are hypersensitive to Adgar 0.1% or any of its components.

Erythema, scaling, dryness, pruritus, burning sensation, skin irritation, stinging unburn, acne flares, etc. are commonly seen during the first month of therapy but usually lessen with continued use of the medication.

Use Adgar 0.1% during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in breast milk. Exercise caution when administering Adgar 0.1% to a nursing mother.

Adgar 0.1% should not be applied to cuts, abrasions, eczematous or sunburned skin.

Store in a cool (below 25°C) and dry place protected from light and moisture. Keep out of the reach of children. Keep the tube tightly closed after use.

Safety and effectiveness in children below 12 years of age have not been established.

Topical retinoid and related preparations

Adgar 0.1% acts on retinoid receptors that are commonly found in the skin of face, back and chest. Biochemical and pharmacological studies have demonstrated that Adgar 0.1% is a modulator of cellular differentiation, keratinization, and inflammatory processes, all of that represent important features in the pathology of acne vulgaris. Adgar 0.1% binds with specific retinoic acid nuclear receptors that normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. Absorption of Adgar 0.1% through human skin is low.

Use Adgar 0.1% during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in breast milk. Exercise caution when administering Adgar 0.1% to a nursing mother.